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Abstract 
Inositol I ,4,Qrisphosphate (IP,)-mediated Ca2+ signaling plays important roles in cellular responses to extracellular stimuli. We recently succeeded 
in cloning human counterparts of the three subtypes derived from separate genes. Using the cDNA sequences type-specific to these subtype receptors, 
we here analyzed the expression profile of IP,R subtypes in stimulated and unstimulated human hematopoietic ell lines representing T cells, B cells, 
neutrophils, macrophages, erythrocytes and megakaryocytes. Northern and dot blot analysis showed that each IP,R subtype is expressed ifferently 
in these cells and that the expression profile in each cell is dynamically changed upon stimuli which induce differentiation. Moreover, most of these 
cells were found to simultaneously express at least two different subtype r ceptors. 
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1. Introduction 
Most of cellular responses to various extracellular 
stimuli are coupled to G protein, which activates phos- 
pholipase C to hydrolize phosphatidylinositol 4,5- 
biphosphate to produce IP, and diacylglycerol. IP, binds 
to its specific intracellular receptors and releases Ca*’ 
from intracellular Ca*’ stores [ 11. Generation of IP3 also 
leads to Ca*’ influx via plasma membrane channels by 
an unidentified mechanism [2]. 
Progenitor cells in bone marrow proliferate and differ- 
entiate to multiple and distinct cell lineages [3]. Cell type- 
specific responses, such as cytokine production [4], dif- 
ferentiation to antibody-producing cells [5], chemotaxis 
[6], and phagocytosis [7], are initiated by stimulation of 
cell surface receptors followed by intracellular signal 
transduction: Ca2’ plays important roles in these proc- 
esses. Phosphatidylinositol (PI) turnover [8], as well as 
the presence of IP, binding activity [9], have been re- 
ported for cells of bone marrow origin. Up-regulation of 
IP, binding activity in response to retinoic acid (RA), 
dimethylsulphoxide (DMSO) or vitamin D, have also 
*Corresponding author. Fax: (81) (427) 268 330. 
Abbreviations: IP,, inositol 1,4,5_trisphosphate; IP,R, IP, receptor; PI, 
phosphatidylinositol; RA, ratinoic acid; DMSO, dimethylsulphoxide; 
PCR, polymerase chain reaction; TPA, l2-o-tetradecanoylphorbol-I 3- 
acetate; NBT, Nitroblue tetrazolium; MLP, N-formyl-L-methionyl-L- 
leucyl+phenylalanine; IL-3, interleukin-3; GM-CSF, granulocyte 
macrophage colony stimulating factor. 
been reported for HL-60 [ 10,111. In these preceding stud- 
ies, IP3 receptor (IP,R) was characterized only by IP, 
binding, Northern blot and polymerase chain reaction 
(PCR) analysis using sequence information derived from 
cDNA of murine IP3R type 1 enriched in cerebellar 
Purkinje cells. 
Molecular cloning studies have shown that there is a 
family of IP,Rs. Full-length cDNAs for IP,R subtypes, 
termed IP,R type 1,2 and 3, have been isolated [ 1,12-l 61. 
We recently succeeded in cloning human counterparts of 
these IP,R subtypes 117,301. Using subtype-specific 
cDNA regions as hybridization probes, we have first 
found that all three subtypes of IP,R are expressed in 
some lymphocyte cell lines [17]. In this study, we have 
examined the expression profiles of IP,R subtypes in 
human hematopoietic ell lines of most lineages, and the 
dynamic change of the expression of these subtypes in 
response to stimuli which induce cell differentiation. 
2. Materials and methods 
2. I. Cells and cell cultures 
The cell lines K562, HEL, CMK, ML-I, HL-60, KU812F and U937 
were maintained in RPMI-1640 medium supplemented with 10% heat- 
inactivated fetal calf serum, 4 mM glutamine, 25 U/ml penicillin and 
25 mg/ml streptomycin. HPB-ALL, Jurkat, HUT-78, Raji, Namalwa, 
RPM11788, Jijoye and THP-1 were maintained in the above-described 
medium supplemented further with 50 mM 2-mercaptoethanol. 
2.2. Induction of cell differentiation 
K562 were treated with 50 mM hemin for 5 days. Cells were collected, 
broken open by freeze-thawing, and centrifuged at 200 x g for IO min 
and then at 10,000 x g for 45 min. The hemoglobin content of the 
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supernatant was measured by scanning spectrophotometry [18,19]. 
CMK were treated with IO ng/ml12-o-tetradecanoylphorbol-13-acetate 
(TPA) for 2 days. Cell surface antigens were detected by immunofluo- 
rescence assay using mouse monoclonal antibodies Y2/51 and AN51 
(Dako Japan, Japan) which recognize platelet membrane glycoprotein 
GP IIIa and platelet GP Ib [20,21], respectively. THP-1 and U937 were 
treated with 10 n&ml TPA or 100 nM retinoic acid (RA) [22-241. HL-60 
cells were treated with 10 ng/ml TPA, 100 nM RA or 1.25% DMSO in 
serum-free medium [25-281. cl-Naphthylacetate esterase activity was 
determined by a chromogenic assay kit (Diagnostics) from Sigma 
(USA). Nitroblue tetrazolium (NBT) reduction was assayed as de- 
scribed [28]. The phagocytic activity of stimulated and unstimulated 
THP-1 was measured using sheep erythrocytes [28]. 
2.3. Northern and dot blot analysis 
Total RNA was extracted and purified by the cesium chloride centrif- 
ugation method [29]. Poly(A)’ RNA was purified with oligo(dT)-cellu- 
lose [29]. Poly(A)’ RNA (3 @lane) was electrophoresed in 1% formal- 
dehyde-agarose gels and transferred to nylon membranes (Hybond N’, 
Amersham, UK). For dot blot analysis, Poly(A)’ RNA was denatured 
and dotted to nylon membranes Hybond N’ (0.5,l and 3 &dot). These 
blots were hybridized with the r’P]cDNA probe specific to each sub- 
type of IP,R. Parts of the cDNAs, nucleotides 4833-5443 of mouse 
IP,R type 1 in pBactS-Cl [I], nucleotides 4830-5669 of human IP,R 
type 2 in pBluescript-IP,R2, and nucleotides 4742-5694 of human IP,R 
type 3 in pcDNAI-IP,R3 [17], were cut-out by appropriate restriction 
enzymes and labeled by the random primer reaction. Our recent cloning 
of the full-length cDNA of the human type 1 receptor [30] indicates ca. 
90% identity in the selected region between mouse and human IP,R type 
1. Blotted membranes were hybridized in a solution of 5 x SSPE 
(0.9 M NaCI, 0.8 M sodium phosphate, 5 mM EDTA, pH 7.7), 0.5% 
SDS, 5 x Denhardt’s reagent and 20 pg/ml salmon sperm DNA at 65” C 
with 0.5 x IO6 cpm/ml of probes, and washed in 0.2 x SSPE containing 
0.1% SDS at 60, 55 and 65°C for type 1, type 2 and type 3 probes, 
respectively. The cDNA probe to human c-rnyc was cut-out by PstI 
from pMYC7.4 [31]. For detection of human /I-actin mRNA, the full 
coding region was amplified by PCR [32]. Radioactivity was detected 
with an image analyzer (BAS2000; Fuji Film, Japan). 
3. Results and discussion 
3.1. Subtype-specific probes for mRNA detection 
Although the three IP,R subtypes how high sequence 
homology, they have subtype-specific diverged regions 
A 
Type 1 
patchily distributed throughout the entire stretch of 
their sequences [17]. We selected ca. 0.8-kb sequences 
immediately upstream of the transmembrane domains 
for Northern blot and dot blot hybridization. 
The sequence identities among these regions of the 
three receptors are 60,47 and 51%, for type l/type 2, type 
2ltype 3 and type 3ltype 1, respectively; we observed no 
cross-hybridization under the conditions employed in the 
following experiments. 
3.2. IP,R subtypes expressed in human hematopoietic 
cell lines 
Northern blot hybridization analysis was carried out 
using the subtype-specific cDNA probes. Human hema- 
topoietic cell lines with respect o their lineage, megakar- 
yoblastic cell lines (HEL, CMK) [20,21,33], an erythro- 
blastic cell line (K562) [19], a myeloblastic cell line 
(ML-l) [34], a promyelocytic cell line (HL-60), a mono- 
blastic cell line (U937), a monocytic cell line (THP-1) 
[28], a basophilic cell line (KU812F) and lymphocytic 
cell lines (HPB-ALL, Jurkat, HUT-78, Raji, Namalwa, 
RPM11788, Jijoye) were investigated. 
Interestingly, most of the cell lines expressed more 
than one type of IP,R simultaneously (Fig. 1). We ob- 
served a single band of about lo-kb in length that hybrid- 
ized to IP,R type 1 and type 3 probes. When the probe 
for IP,R type 2 was used double bands of about lo-kb 
in length were detected as shown in HL-60 and Jurkat. 
This indicates the presence of different polyadenylation 
sites or splicing variants in IP,R type 2 in hematopoietic 
cell lines. Similar results have been reported for the ro- 
dent IP,R type 2 in peripheral tissues [12,13,35]. The 
presence of splicing variants has also been reported for 
IP,R type 1 [36,37]. 
The expression profiles of the IP,R subtypes were 
quite different among these cell lines. In the erythroblas- 
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Fig. 1. Northern blot analysis of inositol 1,4,5_triphosphate receptor subtypes in human hematopoietic ell lines. Poly(A)’ RNAs of K562 (lane I), 
HEL (lane 2), CMK (lane 3), ML-1 (lane 4), HL-60 (lane 5), KU812F (lane 6). THP-1 (lane 7) U937 (lane 8), Jurkat (lane 9 in A, lane 2 in B), Raji 
(lane 10 in A, lane 4 in B), HPB-ALL (lane 1 in B), HUT-78 (lane 3 in B), Namalwa (lane 5 in B), RPM11788 (lane 6 in B) and Jijoye (lane 7 in 
B) were electrophoresed, blotted on nylon membranes and detected by subtype-specific cDNA probes to nucleotides 4833-5443 of type 1 (top panel), 
nucleotides 4830-5669 of type 2 (middle) and nucreotides 4742-5694 of type 3 (bottom). 
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tic cell line K562, IP,R type 3 was dominantly expressed, 
while type 1 was not detected. In the megakaryoblastic 
cell lines, HEL and CMK, the mRNAs of IP,R types 1 
and 2 were clearly detected but that of IP,R type 3 was 
not. The T and B cell lines, Jurkat and Raji, displayed 
higher levels of expression of IP,Rs types 2 and 3. As 
shown in Fig. lB, we also analyzed the expression of 
IP,R subtypes in several T cell lines (HPB-ALL, Jurkat, 
HUT-78) and B cell lines (Raji, Namalwa, RPM11788 
and Jijoye): each of these cell lines is thought to be at a 
different stage of differentiation. In these cell lines, with 
the exception of HUT-78, both IP,R types 2 and 3 were 
detected while the type 1 receptor was only slightly de- 
tected under the experimental conditions used. This re- 
sult agees with PCR analysis of murine thymus where 
mRNAs of only IP,R types 2 and 3 were detected [35]. 
In HUT-78, a more mature T cell line than HPB-ALL 
and Jurkat, the type 3 receptor was dominant and tye 
type 2 receptor was hardly detected. The different behav- 
iors of these T cell lines have been reported for inter- 
leukin-2 production [38,39] and intracellular Ca” incre- 
ment after triggering formation of the T cell receptor- 
CD3 complex. It is reported that Ca2’ flux in HPB-ALL 
is almost solely dependent upon extracellular Ca2’ and 
is not coupled with PI turnover [40]. It is curious that the 
cell lines that express IP,Rs type 2 and type 3 at the 
highest levels are the T cell lines. Thus, the functions of 
these IP,R subtypes in T cells should be carefully studied 
with respect to regulation of their channel activity and 
subcellular localization, since there are reports by elec- 
trophysiology showing the presence of IP,-induced Ca2’ 
influx [41,42]. In Jijoye, the most mature of the B cell 
lines described above, the ratio of the expression levels 
of IP,R type 2: type 3 was considerably higher than those 
in RPM11788 and Raji. No significant difference was 
observed in the Ca2’ response via surface IgM in murine 
B cells of either mature or immature stages in develop- 
ment, although the Ca*’ flux in the immature B cells was 
reported to be uncoupled with PI turnover. Moreover, 
the intracellular Ca” level at the resting stage of imma- 
ture B lymphocytes is higher than that in mature cells 
[43]. Thus, such a difference in the expression of .IP,R 
subtypes in these B cell lines may be closely related to 
their characteristic intracellular Ca2’ metabolism. The 
subcellular localization of type 2 and type 3 receptors in 
T and B lymphocytes should be analyzed in detail by 
electron microscopy to determine whether the receptors 
are localized on the endoplasmic reticulum and/or 
plasma membrane. Recently, the presence of IP,R in the 
plasma membrane of a B cell line has been suggested by 
electrophysiology [44]. 
The myeloblastic cell line, ML-l, and the promyelo- 
cytic cell line, HL-60, expressed ifferent levels of IP3R 
type 3, while mRNA levels of IP,R types 1 and 2 were 
similar between these two cell lines. The expression pro- 
file of the basophilic cell line, KU812F, is characteristic 
(3-actin 
Fig. 2. Change in expression of inositol 1,4,5-trisphosphate r ceptor 
subtypes accompanied by the differentiation of human hematopoietic 
cell lines. Poly(A)’ RNA from cell lines before and after differentiation 
was analyzed by dot blot analysis. The panels from left to right show 
autoradiograms of blots probed with IP,R type 1, IP,R type 2, IP,R 
type 3 and /I-actin, respectively. A single blotted membrane was used 
for reprobing. For each cell, 0.5, 1 and 3 pg of poly(A) RNA were 
blotted from right to left. THP-1 (lanes l-3), U937 (lanes 4-6) K562 
(lanes 7-9) and CMK (lanes IO,1 1) were stimulated with retionic acid 
(lanes 2,5), TPA (lanes 3,6, II), hemin (lane 8), and IL-3 plus GM-CSF 
(lane 9). 
because it almost solely expresses the IP,R type 2 mes- 
sage. 
Although both THP-1 and U937 belong to monocyte/ 
macrophage-like cell lines, the expression of IP,R sub- 
types in these two cell lines was considerably different. 
IP3R type 3 was dominantly expressed in U937, while it 
was not detected in THP- 1. Conversely, the expression 
of IP,R type 1 in THP-1 exceeded that in the U937 cell 
line more than ten times. U937 and THP-1 were estab- 
lished from histiocytic lymphoma cells and peripheral 
blood cells, respectively [45,46], and have different basal 
levels of phagocytic activity [23]. The specific expression 
of IP,R subtypes in these two cell lines may reflect their 
different cellular functions. 
3.3. Changes in subtype-speciJic IP,R expression 
accompanied by cell-differentiation 
The three monocytic cell lines, HL-60, THP-1 and 
U937, represent cells at different stages of differentiation 
[28] with distinct cellular functions regulated by Ca” 
mobilization more or less mediated by IP3R [47,48]. The 
different expression profiles of the IP,R subtypes in these 
three cell lines (Fig. 1) prompted us to examine if stimuli 
which induce cell differentiation and/or activation also 
cause a change in the expression profiles of the IP,R 
subtypes. THP-1 and U937 cells were induced to macro- 
phage-like cells by treatment with RA and TPA [22-241. 
By microscopic observation of cellular a-naphthylace- 
tate esterase activity, these cell lines in the unstimulated 
state showed weak but apparently positive staining, and 
the staining was intensified after stimulation (data not 
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Fig. 3. Cell differentiation of HL-60 coupled with change in subtype expression of inositol 1,4,5-trisphosphate r ceptors. Poly(A)’ RNA from 
unstimulated and stimulated HL-60 cells was analyzed by Northern blot analysis. (A) RNA from HL-60 unstimulated (lane I), stimulated with DMSO 
for 5 days (lane 2), RA for 5 days (lane 3), TPA for 2 days (lane 4) were probed with type I probe (first panel), type 2 probe (second), type 3 probe 
(third) and j3-actin probe (fourth). (B) Time-course of IP,Rs expression upon differentiation. HL-60 cells were treated with TPA or RA for the 
indicated times. (C) Cells were also incubated for 48 h in the presence of TPA with or without 10 mg/ml cycloheximide. For controls, the blots were 
probed with /zI-actin and c-myc. A single blotted membrane was used for reprobing. 
shown). The result indicates that unstimulated THP-1 
and U937 cells already have some macrophage proper- 
ties and differentiate in the presence of the inducer to a 
more mature state. The phagocytic activity of THP-1 
against sheep erythrocytes increased from 48% to 70% 
following RA stimulation. Interestingly, when THP- 1 
cells were stimulated with RA, IP,R types 1 and 2 were 
induced. TPA suppressed the expression of IP,R type 1 
in THP-1 and U937, although that of IP,R type 2 was 
enhanced (Fig. 2). 
In contrast to THP-1 and U937, HL-60 differentiates 
to both monocyte/macrophage and granulocytic lineages 
depending on the nature of the inducer [25-271. TPA 
treatment leads HL-60 to become macrophage-like cells 
[25]. TPA-stimulated HL-60 cells with increased adher- 
ence and a-naphthylacetate esterase activity showed en- 
hanced (IP,R types 1 and 2) and decreased (IP3R type 3) 
expression of IP,Rs (Fig. 3A,B). These differentiated 
cells have been reported to have increased phagocytic 
activity as a result of induction of Fc receptors [22,49,50]. 
Our studies suggest that the Ca2’ signalling pathway to 
phagocytosis [7] may be mediated by IP,R type 2, which 
is increased by stimuli leading cells to become pha- 
gocytes. 
HL-60 cells were induced to granulocyte-like cells by 
sitmulation with DMSO or RA, as judged by NBT stain- 
ing [25,27]. More than 80% of the cells were positive for 
NBT reduction by microscopic observation (data not 
shown). Like the TPA stimulation described above, 
DMSO and RA also induced the cells to express higher 
levels of IP,R types 1 and 2, and suppressed the expres- 
sion of IP,R type 3 (Fig. 3A,B). It is remarkable that the 
IP,R type 2 mRNA level was elevated more than ten 
times in DMSO- or RA-stimulated HL-60. This eleva- 
tion by DMSO and RA stimulation exceeded that of 
TPA stimulation which leads the cells to become mon- 
ocyte/macrophage like cells (Fig. 3A). Bradford et al. 
reported that functional IP,R is induced in HL-60 differ- 
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entiated to the granulocytic lineage [lo] and a single 
poly(A)’ RNA species of IP,R homologous to the mur- 
ine Purkinje cell type IP,R (type 1) is increased [l 11. Our 
studies described here, using subtype-specific probes, 
have revealed that the molecular species of IP,R elevated 
by the stimuli is mainly type 2. In human neutrophils, PI 
turnover and a transient increase in cytosolic free Ca” 
are required for migration and chemotaxis induced by 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) 
[51]. Thus, it is of great interest to determine how the 
specific types of IP,R are involved in regulation of the 
intracellular CA2+ mobilization associated with the be- 
havior of monocytelmacrophage-like c lls. 
Interestingly, the increment of IP,R mRNA levels is 
biphasic, with the first peak at 1 h and the second at 
2448 h, as shown in Fig. 3B. The induction of these 
receptors seems to be independent of protein synthesis 
since cycloheximide does not inhibit the induction 
(Fig. 3C). Many of the early response genes, such as 
c-myc, are those of transcriptional factors and therefore 
essential for the differentiation of HL-60 [52,53]. Fig. 3B 
indicates that the elevation of c-myc mRNA is somehow 
associated with the first phase elevation of mRNA of 
IP,R types 2 and 3. It is widely accepted that intracellular 
Ca2’ is a major regulatory factor of cell differentiation 
[54]. Since cell differentiation is regulated by cascades of 
gene expression, it is important to know how and where 
the two IP,R sybtypes are involved in those cascades. 
CMK cells, which release platelet-like particles, are 
believed to be an ideal model for studying human 
megakaryocytopoiesis and for elucidating the biosyn- 
thetic process of megakaryocyte/platelet-specific pro- 
teins [21]. CMK cells were induced to cells having prop- 
erties of mature megakaryocytes in the presence of TPA 
[20,21], as assessed by expression of the cell surface anti- 
gens, GPIb/GPIIIa (data not shown). Dot blot analysis 
showed that the levels of expression of IP,R types 1 and 
2 in these cells do not change before and after the stimu- 
lation. The result leads to the idea that platelets also 
retain these two IP,R subtypes. Elevation of intracellular 
Ca” plays essential roles in the induction of platelet 
aggregation and secretion by thrombin, collagen, ade- 
nosine S-diphosphate, platelet activating factor and 
other agonists [55]. Thus, IP,R types 1 and 2 may play 
essential roles in these platelet responses. 
K562 cells are pluripotent stem cells [56] which are 
induced to the erythroid lineage by stimulation with 
hemin [19]. Unstimulated K562 cells expressed clearly 
detectable amounts of IP,R types 2 and 3, and much 
lower amounts of IP3R type 1. Induction of K562 cells 
with hemin, as assessed by the production of hemoglobin 
(data not shown), was found to be associated with the 
down-regulation of these two receptor subtypes. Stimu- 
lation with IL-3 plus GM-CSF is known to induce my- 
eloid progenitors hematopoietic growth and maturation 
[57,58]. When K562 was treated with IL-3 and GM-CSF, 
195 
mRNA synthesis for IP,R type 2 was found to be prohib- 
ited while no apparant change was observed that of IP,R 
types 1 and 3. The result is quite different from those 
described by Bradford et al. who reported that these two 
cytokines induce an increase in IP,R as judged by an 
increased Ca” release from non-mitochondrial Ca2+ 
stores, Northern blot and PCR analysis using the IP,R 
type 1 sequence [59]. The discrepancy remains to be ex- 
amined. 
In summary, the results presented in this work indicate 
that the three IP,R subtypes are expressed cell-specifi- 
cally in leukemia and lymphoma cell lines, and that the 
expression of these subtypes is specifically regulated dur- 
ing differentiation. These results suggest that the expres- 
sion of the IP3R subtypes changes dynamically in har- 
mony with changes in cell functions. However, the 
molecular mechanisms of their regulation, in addition to 
the differences in the functions of each IP,R, remain to 
be studied. Most of the cells studied here express two or 
three IP,R subtypes simultaneously: it is also particu- 
larly interesting to examine whether they exist as ho- 
motetramers or heterotetramers, or whether the IP,R 
subtypes are differently located in the cells. 
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